herb · for bloating
Berberine
Meant to knock back gas-producing bacteria and settle the gut muscle.
Say that in clinical terms
Berberine has antimicrobial activity against gas-producing bacteria, supports motility through smooth muscle regulation, reduces intestinal inflammation via NF-kB inhibition, and activates AMPK to improve gut metabolic function.
How strong is the research?
1 paper read.
Who was studied: Patients with diarrhoea-type IBS at a single Chinese hospital.
The existing citation (10.1002/ptr.5475) is an 8-week RCT of berberine hydrochloride 400 mg twice daily in 132 IBS-D patients. Its confirmed primary endpoints are diarrhea frequency, abdominal pain frequency, and urgent need for defecation. Secondary outcomes are a composite IBS symptom score, depression scale, anxiety scale, and quality of life — none labelled specifically as bloating or abdominal distension. PubMed searches combining berberine with bloating-specific terms return zero results in every combination tried. The only study found measuring distension with berberine is a 2024 Belgium observational study of berberine plus curcumin (a combination product, not an RCT), which showed 4
How much to take
daily (split with meals)
500–1500 mg
Take 500mg 2-3 times daily with meals. Start with low dose and increase gradually. May interact with some medications.
Before you take it
- No NIH ODS Tolerable Upper Intake Level (UL) has been established for berberine; clinical trial data supports doses up to approximately 1.5 g/day for up to 6 months, but long-term safety data beyond 6 months is not well characterized.
- Potent quasi-irreversible inhibitor of CYP2D6 (approximately 9-fold suppression) and inhibitor of CYP3A4 and CYP2C9; raises clinically significant drug interaction risk with a large portion of prescription medications whose metabolism depends on these pathways.
- Contraindicated in pregnancy (crosses the placenta; associated with neonatal jaundice and kernicterus risk in newborns) and during breastfeeding.
- Additive hypoglycemia risk when co-administered with antidiabetic agents including metformin, insulin, and sulfonylureas.
- Commonly reported gastrointestinal adverse effects in clinical trial participants include nausea, constipation, abdominal discomfort, and diarrhea.
- Antibiotic-like modulation of gut microbiota composition, including potential suppression of beneficial species; long-term microbiome consequences in humans are not established.
- Berberine itself can cause abdominal bloating and distension as an adverse effect in a subset of clinical trial participants, which is directly contrary to the indication for this symptom; individual responses vary.
When to take it
Best taken: with food
What we make of it
The trial measured diarrhoea, pain and urgency. Bloating was not among them.
The detail
What the study set out to measure was how often people had diarrhoea, how much pain they were in, and how urgently they needed the toilet. Bloating was not a stated outcome, and the participants had a specific IBS diagnosis.